Blinatumomab for the treatment of acute lymphoblastic leukemia: an update

被引:0
作者
Rausch, Caitlin R. [1 ]
Paul, Shilpa [1 ]
Nasnas, Patrice E. [2 ]
Kantarjian, Hagop [2 ]
Jabbour, Elias J. [2 ]
机构
[1] Univ Texas MD Anderson Canc Ctr, Dept Clin Pharm, Houston, TX 77030 USA
[2] Univ Texas MD Anderson Canc Ctr, Dept Leukemia, 1515 Holcombe Blvd,Unit 0428, Houston, TX 77030 USA
来源
EXPERT OPINION ON ORPHAN DRUGS | 2019年 / 7卷 / 02期
关键词
Acute lymphoblastic leukemia; blinatumomab; minimal residual disease; relapsed/refractory; MINIMAL RESIDUAL DISEASE; ANTIBODY BLINATUMOMAB; ADULT PATIENTS; HYPER-CVAD; SINGLE-ARM; PHASE-II; CHEMOTHERAPY; REGIMEN; RELAPSE; SAFETY;
D O I
10.1080/21678707.2019.1571408
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Introduction: Blinatumomab is a first-in-class bispecific T-cell engager (BiTE) antibody that has demonstrated high response rates, including minimal or measurable residual disease (MRD) negativity, in the treatment of acute lymphoblastic leukemia (ALL). As a single agent, blinatumomab has demonstrated significant activity in patients with both relapsed/refractory Philadelphia chromosome-negative and Philadelphia chromosome-positive disease and in patients with persistent MRD. Its unique mechanism of action accounts for its ability to induce durable responses as well as its side effect profile. Areas covered: This manuscript will review the place in therapy for blinatumomab as well as the phase I, phase II, and phase III clinical trials which led to its development and FDA approval for the treatment of ALL. Expert opinion: Blinatumomab is a welcomed addition to the available treatment options for patients with relapsed or refractory ALL. Furthermore, it is currently the most effective treatment in eradicating MRD, and subsequently allowing patients to proceed to allogeneic stem cell transplantation. Improved efficacy is observed in patients treated earlier and in those with lower disease burden, therefore continued evaluation of blinatumomab in combination with chemotherapy in the frontline treatment setting is essential.
引用
收藏
页码:41 / 46
页数:6
相关论文
共 24 条
[1]   Safety and Efficacy of Blinatumomab in Combination With a Tyrosine Kinase Inhibitor for the Treatment of Relapsed Philadelphia Chromosome-positive Leukemia [J].
Assi, Rita ;
Kantarjian, Hagop ;
Short, Nicholas J. ;
Daver, Naval ;
Takahashi, Koichi ;
Garcia-Manero, Guillermo ;
DiNardo, Courtney ;
Burger, Jan ;
Cortes, Jorge ;
Jain, Nitin ;
Wierda, William ;
Chamoun, Salim ;
Konopleva, Marina ;
Jabbour, Elias .
CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2017, 17 (12) :897-901
[2]   Tumor regression in cancer patients by very low doses of a T cell-engaging antibody [J].
Bargou, Ralf ;
Leo, Eugen ;
Zugmaier, Gerhard ;
Klinger, Matthias ;
Goebeler, Mariele ;
Knop, Stefan ;
Noppeney, Richard ;
Viardot, Andreas ;
Hess, Georg ;
Schuler, Martin ;
Einsele, Hermann ;
Brandl, Christian ;
Wolf, Andreas ;
Kirchinger, Petra ;
Klappers, Petra ;
Schmidt, Margit ;
Riethmueller, Gert ;
Reinhardt, Carsten ;
Baeuerle, Patrick A. ;
Kufer, Peter .
SCIENCE, 2008, 321 (5891) :974-977
[3]  
Dombret H, 2017, HAEMATOLOGICA, V102, P179
[4]   Outcome of 609 adults after relapse of acute lymphoblastic leukemia (ALL); an MRC UKALL12/ECOG 2993 study [J].
Fielding, Adele K. ;
Richards, Susan M. ;
Chopra, Rajesh ;
Lazarus, Hillard M. ;
Litzow, Mark R. ;
Buck, Georgina ;
Durrant, I. Jill ;
Luger, Selina M. ;
Marks, David I. ;
Franklin, Ian M. ;
McMillan, Andrew K. ;
Tallman, Martin S. ;
Rowe, Jacob M. ;
Goldstone, Anthony H. .
BLOOD, 2007, 109 (03) :944-950
[5]   Bispecific T-Cell Engager (BiTE) Antibody Construct Blinatumomab for the Treatment of Patients With Relapsed/Refractory Non-Hodgkin Lymphoma: Final Results From a Phase I Study [J].
Goebeler, Maria-Elisabeth ;
Knop, Stefan ;
Viardot, Andreas ;
Kufer, Peter ;
Topp, Max S. ;
Einsele, Hermann ;
Noppeney, Richard ;
Hess, Georg ;
Kallert, Stefan ;
Mackensen, Andreas ;
Rupertus, Kathrin ;
Kanz, Lothar ;
Libicher, Martin ;
Nagorsen, Dirk ;
Zugmaier, Gerhard ;
Klinger, Matthias ;
Wolf, Andreas ;
Dorsch, Brigitte ;
Quednau, Beate D. ;
Schmidt, Margit ;
Scheele, Juergen ;
Baeuerle, Patrick A. ;
Leo, Eugen ;
Bargou, Ralf C. .
JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (10) :1104-+
[6]  
Goekbuget N, 2018, LONG TERM SURVIVAL A, P43
[7]   Blinatumomab for minimal residual disease in adults with B-cell precursor acute lymphoblastic leukemia [J].
Goekbuget, Nicola ;
Dombret, Herve ;
Bonifacio, Massimiliano ;
Reichle, Albrecht ;
Graux, Carlos ;
Faul, Christoph ;
Diedrich, Helmut ;
Topp, Max S. ;
Brueggemann, Monika ;
Horst, Heinz-August ;
Havelange, Violaine ;
Stieglmaier, Julia ;
Wessels, Hendrik ;
Haddad, Vincent ;
Benjamin, Jonathan E. ;
Zugmaier, Gerhard ;
Nagorsen, Dirk ;
Bargou, Ralf C. .
BLOOD, 2018, 131 (14) :1522-1531
[8]  
Jabbour E, 2018, HSCT ADULTS RELAPSED
[9]   Blinatumomab versus Chemotherapy for Advanced Acute Lymphoblastic Leukemia [J].
Kantarjian, Hagop ;
Stein, Anthony ;
Goekbuget, Nicola ;
Fielding, Adele K. ;
Schuh, Andre C. ;
Ribera, Josep-Maria ;
Wei, Andrew ;
Dombret, Herve ;
Foa, Robin ;
Bassan, Renato ;
Arslan, Onder ;
Sanz, Miguel A. ;
Bergeron, Julie ;
Demirkan, Fatih ;
Lech-Maranda, Ewa ;
Rambaldi, Alessandro ;
Thomas, Xavier ;
Horst, Heinz-August ;
Brueggemann, Monika ;
Klapper, Wolfram ;
Wood, Brent L. ;
Fleishman, Alex ;
Nagorsen, Dirk ;
Holland, Christopher ;
Zimmerman, Zachary ;
Topp, Max S. .
NEW ENGLAND JOURNAL OF MEDICINE, 2017, 376 (09) :836-847
[10]   Blinatumomab treatment of older adults with relapsed/refractory B-precursor acute lymphoblastic leukemia: Results from 2 phase 2 studies [J].
Kantarjian, Hagop M. ;
Stein, Anthony S. ;
Bargou, Ralf C. ;
Grande Garcia, Carlos ;
Larson, Richard A. ;
Stelljes, Matthias ;
Goekbuget, Nicola ;
Zugmaier, Gerhard ;
Benjamin, Jonathan E. ;
Zhang, Alicia ;
Jia, Catherine ;
Topp, Max S. .
CANCER, 2016, 122 (14) :2178-2185